Connect with us

National

188 Crore Covid Vaccine Doses Required To Inoculate 18-Plus Population: Centre – dot newz

Published

on


Around 187 crore Covid vaccine doses will be available in India in 2021, the Centre said.

New Delhi:

The projected 18-plus population in the country is 94 crore and therefore, the total requirement of COVID-19 vaccine doses for the beneficiaries in this age group is 188 crore, but the number may reduce if in the future, single-dose vaccines are approved and used, the government told Parliament on Tuesday.

In a written reply to a question in the Rajya Sabha on whether the present Covid vaccine manufacturing firms have the capacity to produce the required quantity, Minister of State for Health Bharati Pravin Pawar said it is estimated that around 1.87 billion (187 crore) doses will be available between January and December 2021.

In addition, a few vaccines under development may also receive approval and may be available for use to inoculate the eligible population, she added.

In a separate written reply, Ms Pawar said the price of the Covid vaccines declared by the two domestic manufacturers for procurement by private hospitals is Rs 600 for Covishield and Rs 1,200 for Covaxin.

In addition, Rs 948 is the price declared for Sputnik V, which is presently imported in the country.

The government has fixed a maximum service charge of Rs 150 per dose over and above the price of the vaccines for administration at private COVID-19 vaccination centres (CVCs). However, the vaccines continue to be provided for free to all eligible beneficiaries at the government CVCs.

The manufacturers are free to fix the price of the vaccines for procurement by private hospitals. However, the same has to be declared in a transparent manner, which has been done by the firms, the minister said.

Replying to another question, Ms Pawar informed that the Covid vaccines presently available in the country do not have VVMs (Vaccine Vial Monitors).

The storage and transportation of the vaccines from the manufacturer to the site of administration is ensured in a temperature-controlled environment at 2-8 degrees Celsius.

The VVM is manufactured by a single offshore manufacturer and requires end-point studies at various duration to finalise the type to be used on each vaccine.

In view of the global urgency to use Covid vaccines upon development, the requirement of a very high quantity of VVMs and the limited production capacity, the vaccines are being used without VVMs across the world, the minister said.

A robust cold chain network of around 29,000 cold-chain points, along with insulated or refrigerated vaccine vans, is used to ensure the storage and transport of the vaccines in a temperature-controlled environment. The storage temperature is also being monitored on a real-time basis to ensure that the vaccines are not exposed beyond the recommended storage temperature, the reply stated.
 

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

National

Coronavirus Live News Update: India Creates World Record In Vaccinations With 2.5 Crore Doses In A Day – dot newz

Published

on

By


The government had set out with a target of 2.5 crore vaccinations and crossed the mark by 10,390

India crossed 2.5 crore Covid vaccinations in a day for the first time on Friday as the government raced to deliver a record on Prime Minister Narendra Modi’s birthday. Union Health Minister Mansukh Mandaviya tweeted to confirm the “historic” figure.

The government had set out with a target of 2.5 crore vaccinations and crossed the mark by 10,390.

With 34,403 more people testing positive for COVID-19, India’s overall infection tally has increased to 3,33,81,728, while the count of active cases has dipped to 3,39,056, according to Union health ministry data updated on Friday.

The death count due to the disease has climbed to 4,44,248 with 320 more fatalities being recorded, it said.

The number of active cases now comprises 1.03 per cent of the total infections, while the national COVID-19 recovery rate has been recorded at 97.64 per cent, according to the data updated by the ministry.

It said that active COVID-19 cases in the country decreased by 3,867 cases in a span of 24 hours.

Here are the updates on coronavirus (COVID-19) cases:

Over 7 lakh people vaccinated in Assam on PM’s birthday

A total of 7,09,524 people received the COVID-19 vaccine in Assam on Friday as the state government undertook a mega inoculation drive on the occasion of Prime Minister Narendra Modi’s birthday, a bulletin said.

Over 2.16 crore people have been immunised, and 44.02 lakh of them got both doses of the vaccines, it said.

The special drive was conducted in 4,575 COVID Vaccination Centres (CVCs), of which 4,557 were government sites and 18 private ones.



Source link

Continue Reading

National

WHO Emergency Approval For Covaxin Delayed Till October 5 – dot newz

Published

on

By


The assessment of the SAGE working group on the available pieces of evidence will determine EUA.

New Delhi:

World Health Organisation’s (WHO) approval for the emergency use authorisation (EUA) to COVID-19 vaccine Covaxin, developed by the Hyderabad-based Bharat Biotech, is likely to be delayed till October 5.

As per WHO, the Strategic Advisory Group of Experts on Immunization (SAGE) will be meeting on October 5 to granting EUA to Covaxin.

Hanna Nohynek, SAGE member will be introducing session objective setting, an update on regulatory decisions and an overview of Working Group deliverables.

The session will recommend EUA based on the clinical data on Covaxin from phase 1, 2, 3 trial and post-marketing studies on safety, immunogenicity, efficacy and effectiveness.

It will update on global, regional and country-level plans for vaccine safety monitoring.

The assessment of the SAGE working group on the available pieces of evidence will determine EUA.

Meanwhile, Bharat Biotech on Friday said it has submitted all the data to the World Health Organisation (WHO) for Emergency Use Listing (EUL) of its COVID-19 vaccine Covaxin and is awaiting feedback from the UN Public Health Agency.

In a series of tweets, Bharat Biotech said that Covaxin clinical trial was fully compiled and available in June 2021.

“#COVAXIN clinical trial data was fully compiled and available in June 2021. All Data was submitted for Emergency Use Listing (EUL) Application to World Health Organization in early July. We have responded to any clarifications sought by #WHO and are awaiting further feedback,” Bharat Biotech tweeted.

As a responsible manufacturer with past approvals for its other vaccines, the company said it would not find it appropriate to speculate or comment on the approval process and its timelines, it further said.

“We are continuing to work diligently on obtaining WHO EUL at the earliest,” it added.

Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent efficacy to the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

Covaxin was developed by Hyderabad-based Bharat Biotech in association with the Indian Council of Medical Research and the National Institute of Virology. Covaxin, which has been developed in collaboration with the Indian Council of Medical Research (ICMR), contains a whole virion inactivated SARS-CoV-2 vaccine, which is produced in Vero cells.

The vaccine is stable at 2 degrees Celsius to 8 degrees Celsius (refrigerated) and is shipped in a ready-to-use liquid formulation that permits distribution using existing vaccine supply chain channels.

The WHO has so far approved Covid vaccines developed by Pfizer-BioNTech, US pharma majors Johnson & Johnson, Moderna, China’s Sinopharm and Oxford-AstraZeneca for emergency use.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)





Source link

Continue Reading

National

PM Praises Frontline, Health Workers As India Administers Over 2 Crore Doses – dot newz

Published

on

By


PM Praises Frontline, Health Workers As India Administers Record Doses

New Delhi:

As India set a new record on Friday by administering over 2 crores COVID-19 vaccine doses, Prime Minister Narendra Modi dedicated the success of the vaccination drive to the country’s doctors, innovators, administrators, nurses, healthcare and all front-line workers.

“Every Indian would be proud of today’s record vaccination numbers. I acknowledge our doctors, innovators, administrators, nurses, healthcare and all front-line workers who have toiled to make the vaccination drive a success. Let us keep boosting vaccination to defeat COVID-19,” PM Modi tweeted.

Bharatiya Janata Party (BJP) and several state governments have aimed to make Prime Minister Narendra Modi’s birthday historic by setting a record number of Covid vaccinations Friday.

Taking to Twitter, Union Health Minister Mansukh Mandaviya said that the historic feat is a gift to PM Modi on behalf of the health workers and the countrymen.

“#VaccineSeva A gift to Prime minister Narendra Modi on behalf of the health workers and the countrymen. Today, on his birthday, India has crossed the historical figure of administering 2 crore vaccines in a day, setting a new record. Well done India!” Mandaviya tweeted.

India has administered more than one crore COVID-19 vaccines in a day on earlier occasions.The vaccination drive in the country commenced on January 16 with the inoculation of healthcare and frontline workers. At present, India is administering COVID-19 vaccines– Covishield of Serum Institute of India (SII), Bharat Biotech”s Covaxin and Sputnik V.

To ramp up the drive, on April 1, the government had opened Covid-19 vaccination for everyone above the age of 45 years. A month later from May 1, as a part of the third phase of the vaccination drive, India began administering the vaccine in the 18 to 44 years age group.

Since then, the country’s vaccination drive is scaling new heights. On August 9, India’s COVID-19 vaccination coverage crossed the landmark of 50 crores.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)





Source link

Continue Reading

Trending

Copyright © 2017 Dot Newz | Developed by MCVP Group 8